

## Appendix: Tables

1.	Sales January to March 2024 and 2023 .....	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2024 and 2023 .....	3
3.	Product sales Pharmaceuticals Division and constant exchange rate growth YTD March 2024 vs. YTD March 2023 .....	4
4.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth .....	6
5.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States .....	7
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe .....	8
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan .....	9
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International .....	10

## 1. Sales January to March 2024 and 2023

CHF millions	Three months ended 31 March		% change	
	2024	2023	At CER	In CHF
Pharmaceuticals Division	10,921	11,608	2	-6
United States	5,692	5,763	5	-1
Europe	2,200	2,071	11	6
Japan	649	1,390	-45	-53
International*	2,380	2,384	12	0
Diagnostics Division	3,478	3,714	2	-6
Roche Group	14,399	15,322	2	-6

\* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

All figures shown in the table were restated to reflect the shift of the FMI business from Pharma Division to Diagnostics Division

## 2. Quarterly sales and constant exchange rate sales growth by Division in 2024 and 2023

CHF millions	Q1 2023	% change vs. Q1 2022	Q2 2023	% change vs. Q2 2022	Q3 2023	% change vs. Q3 2022	Q4 2023	% change vs. Q4 2022	Q1 2024	% change vs. Q1 2023
Pharmaceuticals Div.	11,608	9	10,903	7	10,861	11	10,893	-2	10,921	2
United States	5,763	7	5,811	8	5,857	11	5,829	5	5,692	5
Europe	2,071	5	2,034	5	2,154	9	2,047	3	2,200	11
Japan	1,390	18	820	8	727	1	808	-50	649	-45
International*	2,384	13	2,238	6	2,123	17	2,209	16	2,380	12
Diagnostics Division	3,714	-28	3,554	-17	3,413	-5	3,770	4	3,478	2
Roche Group	15,322	-3	14,457	0	14,274	7	14,663	0	14,399	2

\* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

All figures shown in the table were restated to reflect the shift of the FMI business from Pharma Division to Diagnostics Division

### 3. Product sales Pharmaceuticals Division and constant exchange rate growth YTD March 2024 vs. YTD March 2023

CHF millions	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	1,658	8	1,180	5	310	8	-	-	168	28
Hemlibra	1,040	8	592	-1	231	17	79	2	138	51
Perjeta	936	-3	343	-7	171	-19	36	-19	386	14
Tecentriq	865	1	436	-9	210	12	86	-4	133	34
Vabysmo	847	108	650	91	138	224	23	33	36	397
Actemra/RoActemra	618	-2	278	-1	188	1	68	5	84	-15
Xolair	496	10	496	10	-	-	-	-	-	-
Kadcyla	483	3	186	-1	145	-2	21	-4	131	19
Phesgo	388	70	126	36	169	55	19	-	74	165
Herceptin	364	-17	67	-22	77	-17	4	-41	216	-14
Evrysdi	356	7	135	16	137	27	20	13	64	-29
Alecensa	355	4	104	4	72	3	43	3	136	5
MabThera/Rituxan	351	-18	204	-21	39	-20	4	-20	104	-11
Avastin	324	-15	99	-22	21	-27	51	-33	153	3
Activase/TNKase	296	4	282	4	-	-	-	-	14	7
Polivy	250	81	117	166	54	42	44	2	35	181
Gazyva	213	16	100	7	62	17	6	-19	45	47
Pulmozyme	112	-6	66	-15	20	0	-	27	26	22
Mircera	96	0	-	-	10	-8	9	-25	77	6
CellCept	94	0	5	-34	32	-	9	-10	48	8
Enspryng	65	37	18	31	7	98	35	25	5	131
Xofluza	47	185	4	257	-	-	-	-	43	180

Rozlytrek	29	66	12	27	5	24	2	27	10	258
Columvi	25	-	16	-	6	-	-	-	3	-
Lunsumio	16	21	13	10	3	103	-	-	-	-
Cotellic	10	-6	4	-14	3	-4	-	-	3	3
Gavreto	9	-5	7	31	1	-28	-	-	1	-81
Elevidys	2	-	-	-	-	-	-	-	2	-
Luxturna	1	-61	1	-61	-	-	-	-	-	-
Ronapreve	1	-100	-	-	1	**	-	-100	-	-
Susvimo	1	11	1	11	-	-	-	-	-	-
Pharma other	573	-27	150	-48	88	-17	90	-29	245	-5
Pharma total sales	10,921	2	5,692	5	2,200	11	649	-45	2,380	12

\* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

\*\* Over 500%

#### 4. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q1 2023	% change vs. Q1 2022	Q2 2023	% change vs. Q2 2022	Q3 2023	% change vs. Q3 2022	Q4 2023	% change vs. Q4 2022	Q1 2024	% change vs. Q1 2023
Ocrevus	1,636	14	1,564	15	1,567	12	1,614	9	1,658	8
Hemlibra	1,034	24	1,053	17	1,025	17	1,035	9	1,040	8
Perjeta	1,049	11	1,033	6	913	0	773	-11	936	-3
Tecentriq	920	15	933	8	938	10	975	5	865	1
Vabysmo	432	*	525	*	656	309	744	160	847	108
Actemra/RoActemra	676	-12	620	2	647	21	687	13	618	-2
Xolair	479	5	552	4	570	3	575	7	496	10
Kadcyla	509	5	492	-5	485	5	480	13	483	3
Phesgo	241	72	276	67	300	61	303	58	388	70
Herceptin	477	-17	401	-22	383	-13	365	-14	364	-17
Evryssi	363	62	342	36	360	41	354	22	356	7
Alecensa	372	9	386	11	368	7	376	7	355	4
MabThera/Rituxan	459	-17	423	-17	378	-13	370	-15	351	-18
Avastin	416	-24	421	-17	373	-18	363	-15	324	-15
Activase/TNKase	302	23	319	9	282	-4	270	-1	296	4
Polivy	150	96	203	129	252	144	232	74	250	81
Gazyva	197	24	205	20	213	22	196	12	213	16
Pulmozyme	127	-5	111	-15	104	-15	110	-6	112	-6
Mircera	105	24	93	-1	120	27	108	4	96	0
CellCept	103	-18	98	-19	94	-9	98	-8	94	0

\* Over 500%

**5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States**

CHF millions	Q1 2023	% change vs. Q1 2022	Q2 2023	% change vs. Q2 2022	Q3 2023	% change vs. Q3 2022	Q4 2023	% change vs. Q4 2022	Q1 2024	% change vs. Q1 2023
Ocrevus	1,188	13	1,158	14	1,146	10	1,192	8	1,180	5
Hemlibra	631	21	616	14	615	15	631	8	592	-1
Perjeta	392	8	371	6	338	-6	235	-35	343	-7
Tecentriq	507	14	493	5	476	4	465	-4	436	-9
Vabysmo	360	*	428	458	532	276	594	142	650	91
Actemra/RoActemra	296	-22	278	6	303	33	346	33	278	-1
Xolair	479	5	552	4	570	3	575	7	496	10
Kadcyla	198	-3	188	-5	182	-2	189	3	186	-1
Phesgo	98	62	111	53	111	54	103	27	126	36
Herceptin	91	-37	85	-23	82	-21	73	-20	67	-22
Evrysdi	124	13	131	19	126	14	124	11	135	16
Alecensa	106	7	115	14	119	4	127	13	104	4
MabThera/Rituxan	274	-21	260	-19	227	-19	226	-22	204	-21
Avastin	133	-25	123	-20	114	-19	114	-9	99	-22
Activase/TNKase	288	23	304	9	267	-5	253	-1	282	4
Polivy	46	35	78	91	106	161	110	173	117	166
Gazyva	99	32	95	18	103	24	98	14	100	7
Pulmozyme	83	-5	75	-16	71	-19	74	-9	66	-15
Mircera	-	-	-	-	-	-	-	-	-	-
CellCept	8	-18	8	-14	6	-34	8	-1	5	-34

\* Over 500%

## 6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q1 2023	% change vs. Q1 2022	Q2 2023	% change vs. Q2 2022	Q3 2023	% change vs. Q3 2022	Q4 2023	% change vs. Q4 2022	Q1 2024	% change vs. Q1 2023
Ocrevus	298	11	286	16	293	10	289	11	310	8
Hemlibra	206	27	213	18	218	22	208	8	231	17
Perjeta	220	1	193	-12	202	0	161	-21	171	-19
Tecentriq	195	11	203	7	230	22	217	2	210	12
Vabysmo	44	-	59	*	82	*	91	406	138	224
Actemra/RoActemra	193	-8	190	0	200	11	192	-1	188	1
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	154	-6	144	-15	148	-6	131	-17	145	-2
Phesgo	114	59	126	55	144	47	150	49	169	55
Herceptin	97	-17	86	-18	88	-9	82	-10	77	-17
Evrysdi	113	74	128	61	133	35	135	39	137	27
Alecensa	73	3	75	5	72	5	72	1	72	3
MabThera/Rituxan	51	0	45	-9	44	-11	40	-15	39	-20
Avastin	30	-45	27	-51	21	-50	20	-43	21	-27
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Polivy	40	93	40	76	56	53	37	-21	54	42
Gazyva	55	25	56	22	63	29	55	18	62	17
Pulmozyme	20	-16	19	-20	18	-18	19	-15	20	0
Mircera	12	-10	11	-9	11	-2	10	-2	10	-8
CellCept	33	1	31	-5	31	-4	28	-14	32	0

\* Over 500%



**7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan**

CHF millions	Q1 2023	% change vs. Q1 2022	Q2 2023	% change vs. Q2 2022	Q3 2023	% change vs. Q3 2022	Q4 2023	% change vs. Q4 2022	Q1 2024	% change vs. Q1 2023
Ocrevus	-	-	-	-	-	-	-	-	-	-
Hemlibra	92	24	100	19	89	5	92	5	79	2
Perjeta	53	2	56	5	52	6	54	3	36	-19
Tecentriq	105	12	109	11	99	5	106	3	86	-4
Vabysmo	21	-	25	299	24	77	28	42	23	33
Actemra/RoActemra	77	0	80	5	75	4	79	3	68	5
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	26	-8	26	-17	25	-15	25	-6	21	-4
Phesgo	-	-	-	-	-	-	4	-	19	-
Herceptin	9	-30	8	-34	7	-35	6	-31	4	-41
Evrysdi	21	47	24	25	22	21	26	19	20	13
Alecensa	50	5	57	7	50	5	55	5	43	3
MabThera/Rituxan	6	-13	7	-15	6	-11	5	-15	4	-20
Avastin	91	-21	86	-25	73	-28	68	-31	51	-33
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Polivy	51	169	57	194	59	178	60	55	44	2
Gazyva	8	-35	12	1	8	-18	10	-4	6	-19
Pulmozyme	-	18	-	-4	-	33	1	-4	-	27
Mircera	14	-22	14	-23	13	-22	13	-22	9	-25
CellCept	12	-8	11	-8	11	-15	11	-12	9	-10

**8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International\***

CHF millions	Q1 2023	% change vs. Q1 2022	Q2 2023	% change vs. Q2 2022	Q3 2023	% change vs. Q3 2022	Q4 2023	% change vs. Q4 2022	Q1 2024	% change vs. Q1 2023
Ocrevus	150	32	120	23	128	50	133	22	168	28
Hemlibra	105	38	124	31	103	39	104	14	138	51
Perjeta	384	22	413	18	321	4	323	21	386	14
Tecentriq	113	34	128	23	133	18	187	39	133	34
Vabysmo	7	-	13	**	18	**	31	**	36	397
Actemra/RoActemra	110	10	72	-9	69	20	70	-3	84	-15
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	131	42	134	11	130	41	135	91	131	19
Phesgo	29	232	39	206	45	151	46	196	74	165
Herceptin	280	-7	222	-22	206	-11	204	-12	216	-14
Evrysdi	105	189	59	39	79	134	69	18	64	-29
Alecensa	143	14	139	13	127	10	122	5	136	5
MabThera/Rituxan	128	-12	111	-14	101	4	99	2	104	-11
Avastin	162	-19	185	1	165	-5	161	-4	153	3
Activase/TNKase	14	17	15	8	15	-1	17	-1	14	7
Polivy	13	340	28	339	31	422	25	214	35	181
Gazyva	35	27	42	29	39	18	33	2	45	47
Pulmozyme	24	10	17	-5	15	14	16	18	26	22
Mircera	79	47	68	7	96	44	85	11	77	6
CellCept	50	-28	48	-28	46	-6	51	-4	48	8

\* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

\*\* Over 500%